Sands Capital Ventures’s Tarsus Pharmaceuticals TARS Stock Holding History

Sands Capital Ventures’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.35M	Hold	85,000	–	–	0.87%	20
2026 Q1	$5.96M	Hold	85,000	–	–	1.42%	14
2025 Q4	$6.96M	Sell	85,000 -85,000	-50%	-$6.35M	1.34%	15
2025 Q3	$10.1M	Hold	170,000	–	–	2.21%	10
2025 Q2	$6.89M	Hold	170,000	–	–	1.36%	12
2025 Q1	$8.73M	Hold	170,000	–	–	2.14%	10
2024 Q4	$9.41M	Hold	170,000	–	–	2.05%	10
2024 Q3	$5.59M	Hold	170,000	–	–	1.57%	10
2024 Q2	$4.62M	Hold	170,000	–	–	1.55%	9
2024 Q1	$6.18M	Sell	170,000 -90,000	-35%	-$2.65M	1.49%	9
2023 Q4	$5.26M	Hold	260,000	–	–	1.46%	10
2023 Q3	$4.62M	Hold	260,000	–	–	1.37%	12
2023 Q2	$4.7M	Hold	260,000	–	–	1.39%	10
2023 Q1	$3.27M	Hold	260,000	–	–	0.81%	12
2022 Q4	$3.81M	Hold	260,000	–	–	1.04%	13
2022 Q3	$4.45M	Hold	260,000	–	–	1.29%	12
2022 Q2	$3.8M	Hold	260,000	–	–	1.04%	13
2022 Q1	$4.37M	Hold	260,000	–	–	0.91%	14
2021 Q4	$5.85M	Hold	260,000	–	–	0.87%	14
2021 Q3	$5.6M	Buy	+260,000	New	+$6.44M	0.84%	11

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Ventures's TARS Position: Q2 2026 in Review

Sands Capital Ventures held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 85,000 shares worth $5.35M. The position accounts for 0.87% of the portfolio, ranked #20.

Sands Capital Ventures first reported a position in TARS in Q3 2021 and has held it in 20 quarters since. The position peaked at $10.1M in Q3 2025. 234 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Sands Capital Ventures held 85,000 shares of Tarsus Pharmaceuticals worth $5.35M as of Q2 2026.
Sands Capital Ventures left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
Tarsus Pharmaceuticals made up 0.87% of Sands Capital Ventures's portfolio in Q2 2026, its #20 holding.
Sands Capital Ventures first reported a position in Tarsus Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
Sands Capital Ventures's Tarsus Pharmaceuticals position peaked at $10.1M in Q3 2025.
234 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Sands Capital Ventures's 13F filing for Q2 2026, filed 13 Aug 2026.